NL-OMON30358已完成不适用
The Breast CARE Study: Capecitabine (Xeloda) combined with Rhenium-188-HEDP in breast cancer patients with bone metastases; a Re-188-HEDP phase I dose escalation study and phase II efficacy study. - The Breast CARE Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Histologically documented carcinoma of the breast.
- •Resistant to taxanes and further antracycline therapy not indicated.
- •Presence of more than one osteoblastic bone metastasis.
- •Life expectancy of at least 3 months.
- •Informed consent.
排除标准
- •Previous chemotherapy within 4 weeks prior to screening.
- •Prior treatment with a systemic radiotherapeutic bone agent within a specified period.
- •Previous external beam therapy within a specified period.
- •Active CNS or epidural brain metastasis.
- •Absolute neutrophil count < 2 10^9/L
- •Platelet count <150 10^9/l
- •Haemoglobin <6 mmol/L
研究者
相似试验
进行中（未招募）
不适用
The Breast CARE Study: Capecitabine (Xeloda®) combined with RHenium-188-HEDP in breast cancer patients with bone metastses; a Re-188-HEDP phase I dose escalation study and phase II efficacy study. - The Breast CARE StudyBreast cancer with painful bone metastases.MedDRA version: 8.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2006-004008-38-NLniversity Medical Center Utrecht40
进行中（未招募）
1 期
Phase II trial of capecitabine (Xeloda®) + nab-paclitaxel (Abraxane®) in patients with metastatic pancreatic cancerEUCTR2013-001714-15-ATMed. Univ. Wien, Klinik f. Innere Med. I, Onkologie30
尚未招募
不适用
Clinical observation on the treatment of breast cancer related lymphedema with oral and external use of the ZhuShui Decoctiobreast cancerITMCTR2200005626Shanghai Hospital of traditional Chinese Medicine
已完成
2 期
XELOX for Metastatic Breast CancerMetastatic Breast CancerNCT00204776University of Wisconsin, Madison37
进行中（未招募）
不适用
A phase II study of Capecitabine in combination with Cisplatin in advanced head and neck Cancer - NDAdvanced or metastatic head and neck cancerLevel: HLTClassification code 10024530EUCTR2006-003775-13-ITOSPEDALE ONCOLOGICO DI BARI43